RxDoctor Payments Data

Shea Arnold, PA

Medical · Rogers, ARNPI 1417192774

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 356 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 38.3% of the total.

$5,662in general payments, 2019–2025

Across 356 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$599
  • Gilead$387
  • Takeda Pharmaceuticals U.S.A., Inc.$371
  • Johnson & Johnson$338
  • Sanofi$332
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$5,62899%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,662 in reported general payments places this provider in the 85th percentile of 133 medical providers in Arkansas.

See all medical providers in Arkansas

Medicare billing

Part B allowed, 2024
$8,493
Medicare patients
94
Services billed
125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide36$31,081
Mesalamine11$6,934
Dexlansoprazole DrDexlansoprazole23$5,148
Ondansetron OdtOndansetron17$3,371
Azathioprine59$1,633
Pantoprazole Sodium94$1,319
CholestyramineCholestyramine (With Sugar)23$1,298
Ursodiol13$1,232
Omeprazole53$780
Colestipol Hcl15$771
Balsalazide Disodium13$771
Esomeprazole Magnesium12$655
Dicyclomine Hcl20$324
ConstuloseLactulose11$184
Furosemide21$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,166$31,08136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 133 medical providers in Arkansas.

Other medical in Rogers

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →